EPO Patent Application: Double-Stranded RNA for RSV-B
Summary
The European Patent Office has published a new patent application, EP2026028971A1, concerning novel double-stranded RNA based on the RSV-B RNA sequence and its therapeutic uses. The publication date is March 18, 2026, and the inventors have not yet been designated.
What changed
This document is a publication of a European patent application (EP2026028971A1) by the European Patent Office (EPO). The application, published on March 18, 2026, relates to novel double-stranded RNA derived from the RSV-B RNA sequence and its potential therapeutic applications, specifically for treating viral infections.
As this is a patent application publication, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property rights and may inform research and development strategies for companies in the pharmaceutical and biotechnology sectors. Compliance officers should note this publication as part of ongoing monitoring of the competitive and IP landscape.
Source document (simplified)
NOVEL DOUBLE-STRANDED RNA BASED ON RSV-B RNA SEQUENCE, AND USE THEREOF
Publication EP2026028971A1 Kind: A1 Mar 18, 2026
Inventors
The designation of the inventor has not yet been filed
IPC Classifications
C12N 15/113 20100101AFI20260207BHEP A61K 31/713 20060101ALI20260207BHEP A61P 31/14 20060101ALI20260207BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.